Cardiac disease in pregnancy and peripartum cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
Peripartum cardiomyopathy ''([[PPCM]])'' is a form of [[dilated cardiomyopathy]] that is defined as a deterioration in cardiac function presenting between the last month of gestation and up to five months post-partum.  
Peripartum cardiomyopathy ''([[PPCM]])'' is a form of [[dilated cardiomyopathy]] that is defined as a deterioration in cardiac function presenting between the last month of gestation and up to five months post-partum.  


The etiology of postpartum cardiomyopathy is unknown. As with other forms of [[dilated cardiomyopathy]], [[PPCM]] involves decrease of the [[left ventricle|left ventricular]] [[ejection fraction]] with associated [[congestive heart failure]] and increased risk of atrial and ventricular [[arrhythmia]]s and even [[sudden cardiac death]].
The etiology of postpartum cardiomyopathy is unknown. Reported prevalence of postpartum cardiomyopathy in United States is estimated to be 1 case per 1300-15,000 live births.  
 
In the US the prevalence is estimated to be 1 case per 1300-15,000 live births. The incidence of peripartum cardiomyopathy is increased in women over the age of 30, in twin pregnancies, in multiparous women, in women with gestational hypertension, those who have received tocolytic therapy, and in african americans.


Treatment for the disease is similar to treatment for [[congestive heart failure]]. [[Delivery]] is the recommeded overall treatment to decrease the volume load, improve ventricular function and simplify the medical management of these patients.
Treatment for the disease is similar to treatment for [[congestive heart failure]]. [[Delivery]] is the recommeded overall treatment to decrease the volume load, improve ventricular function and simplify the medical management of these patients.
Line 34: Line 32:
*Estimates of incidence 1/1300-15000. Previous studies likely overestimated
*Estimates of incidence 1/1300-15000. Previous studies likely overestimated
*More common in women with:
*More common in women with:
:*Multiple pregnancies
:*Multiple pregnancies,
:*African decent
:*African decent,
:*h/o toxemia
:*h/o toxemia,
:*Long-term tocolytic use
:*Long-term tocolytic use,
:*Age>30
:*Age >30,
:*Twin Pregnancy
:*Twin Pregnancy.
 
==Cause==
The etiology of postpartum cardiomyopathy is unknown. As with other forms of [[dilated cardiomyopathy]], [[PPCM]] involves decrease of the [[left ventricle|left ventricular]] [[ejection fraction]] with associated [[congestive heart failure]] and increased risk of atrial and ventricular [[arrhythmia]]s and even [[sudden cardiac death]].
 
==History and Symptoms==
Signs and symptoms are similar to those of normal pregnancy


==Hemodynamic Findings==
==Hemodynamic Findings==
Line 48: Line 52:
!width="225"|Peripartum cardiomyopathy
!width="225"|Peripartum cardiomyopathy
|-
|-
|align="center"|RA ||align="center"|2 || align="center"|11 (2-34)
|align="center"|[[Right atrium]] ||align="center"|2 || align="center"|11 (2-34)
|-
|-
|align="center"|PA ||align="center"|11 || align="center"|39 (18-62)
|align="center"|[[Pulmonary artery]] ||align="center"|11 || align="center"|39 (18-62)
|-
|-
|align="center"| PCW ||align="center"| 6 || align="center"|18 (5-32)
|align="center"|[[Pulmonary capillary wedge pressure]] ||align="center"| 6 || align="center"|18 (5-32)
|-
|-
|align="center"|CO (L/min) ||align="center"| 7 ||align="center"|6  (5-9)
|align="center"|[[CO|Cardiac output (L/min)]] ||align="center"| 7 ||align="center"|6  (5-9)
|-
|-
|align="center"|HR ||align="center"|83 ||align="center"|104  (76-142)
|align="center"|[[Heart rate]] ||align="center"|83 ||align="center"|104  (76-142)
|}
|}


==Treatment of Peripartum Cardiomyopathy==
==Treatment==
* [[Delivery]] is the recommeded overall treatment to decrease the volume load, improve ventricular function and simplify the medical management of these patients.


* [[Digoxin]] and diuretics are Class C
=====Pharmacotherapy:=====
* [[ACE inhibitors]] absolutely contraindicated prepartum ([[hydralazine]] drug of choice)
* [[Digoxin]] and [[diuretics]] are Class C recommendation.
* Anticoagulation recommended ([[Heparin]] prepartum and [[coumadin]] postpartum)
* [[ACE inhibitors]] absolutely contraindicated prepartum ([[hydralazine]] drug of choice).
* [[Anticoagulation]] recommended ([[heparin]] prepartum and [[coumadin]] postpartum).


==Outcome of Peripartum Cardiomyopathy==
==Prognosis==


* Mortality 25-50% (half deaths in first 3 months)
* Mortality 25-50% (half deaths in first 3 months).
* Remainder stable/recover within 6 months
* Remainder stable/recover within 6 months.
* Can recur with subsequent pregnancies
* Can recur with subsequent pregnancies.
* Favorable outcomes with cardiac transplantation
* Favorable outcomes with [[cardiac transplantation]].


==References==
==References==

Revision as of 19:17, 18 April 2012

Cardiac disease in pregnancy Microchapters

Home

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

Exercise Testing

Radiation Exposure

Chest X Ray

Echocardiography

MRI

CT

Catheterization:

Pulmonary artery catheterization
Cardiac catheterization
Cardiac Ablation

Treatment

Cardiovascular Drugs in Pregnancy

Labor and delivery

Resuscitation in Late Pregnancy

Contraindications to pregnancy

Special Scenarios:

I. Pre-existing Cardiac Disease:
Congenital Heart Disease
Repaired Congenital Heart Disease
Pulmonary Hypertension
Rheumatic Heart Disease
Connective Tissue Disorders
II. Valvular Heart Disease:
Mitral Stenosis
Mitral Regurgitation
Aortic Insufficiency
Aortic Stenosis
Mechanical Prosthetic Valves
Tissue Prosthetic Valves
III. Cardiomyopathy:
Dilated Cardiomyopathy
Hypertrophic Cardiomyopathy
Peripartum Cardiomyopathy
IV. Cardiac diseases that may develop During Pregnancy:
Arrhythmias
Acute Myocardial Infarction
Hypertension

Cardiac disease in pregnancy and peripartum cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac disease in pregnancy and peripartum cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac disease in pregnancy and peripartum cardiomyopathy

CDC on Cardiac disease in pregnancy and peripartum cardiomyopathy

Cardiac disease in pregnancy and peripartum cardiomyopathy in the news

Blogs on Cardiac disease in pregnancy and peripartum cardiomyopathy

Directions to Hospitals Treating Cardiac disease in pregnancy

Risk calculators and risk factors for Cardiac disease in pregnancy and peripartum cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Anjan K. Chakrabarti, M.D. [3]

Synonyms and Keywords: PPCM;

Overview

Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy that is defined as a deterioration in cardiac function presenting between the last month of gestation and up to five months post-partum.

The etiology of postpartum cardiomyopathy is unknown. Reported prevalence of postpartum cardiomyopathy in United States is estimated to be 1 case per 1300-15,000 live births.

Treatment for the disease is similar to treatment for congestive heart failure. Delivery is the recommeded overall treatment to decrease the volume load, improve ventricular function and simplify the medical management of these patients.

Definition

Peripartum cardiomyopathy is defined as:

  • Ejection fraction <45% and/or
  • Fractional shortening <30%
  • End-diastolic dimension >2.7 cm/m2 BSA (body surface area)

Common Mimickers

Demographics

  • Estimates of incidence 1/1300-15000. Previous studies likely overestimated
  • More common in women with:
  • Multiple pregnancies,
  • African decent,
  • h/o toxemia,
  • Long-term tocolytic use,
  • Age >30,
  • Twin Pregnancy.

Cause

The etiology of postpartum cardiomyopathy is unknown. As with other forms of dilated cardiomyopathy, PPCM involves decrease of the left ventricular ejection fraction with associated congestive heart failure and increased risk of atrial and ventricular arrhythmias and even sudden cardiac death.

History and Symptoms

Signs and symptoms are similar to those of normal pregnancy

Hemodynamic Findings

Chamber Normal Pregnancy Peripartum cardiomyopathy
Right atrium 2 11 (2-34)
Pulmonary artery 11 39 (18-62)
Pulmonary capillary wedge pressure 6 18 (5-32)
Cardiac output (L/min) 7 6 (5-9)
Heart rate 83 104 (76-142)

Treatment

  • Delivery is the recommeded overall treatment to decrease the volume load, improve ventricular function and simplify the medical management of these patients.
Pharmacotherapy:

Prognosis

  • Mortality 25-50% (half deaths in first 3 months).
  • Remainder stable/recover within 6 months.
  • Can recur with subsequent pregnancies.
  • Favorable outcomes with cardiac transplantation.

References


Template:WikiDoc Sources